← Eichor
Study identifier: NCT05402839 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Screening of Malignant Hyperthermia Susceptible Individuals

Condition: Malignant Hyperthermia  ·  Sponsor: Peking University Third Hospital

PhaseN/A
Planned participants50
Who can joinAll sexes, 0 Years to 100 Years
Healthy volunteersNo

About this study

This study intends to target patients who underwent surgery under general anesthesia during the study period and developed malignant hyperthermia during or after surgery. Therefore, the total sample size was estimated to be about 50 people based on the past incidence of this rare disease. Every year, about 20 patients and their families who developed malignant hyperthermia during or after surgery will participate in this nationwide study (estimated by the current incidence of malignant hyperthermia), and about 1-5 patients will be admitted to Peking University Third Hospital participate in this research. Relevant specimens were collected from malignant hyperthermia (MH) patients and their family members for genetic analysis to determine the mutation of MH-related pathogenic gene loci.

This description comes directly from the study's public registry record.

Talk to the study team

Yinyin Qu, M.D.  ·  +8613466759889  ·  quyinyin@bjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Third HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05402839